STING-ATF3/type I interferon crosstalk: A potential target to improve anti-tumour immunity in chemotherapy-treated urothelial carcinoma

Alexandra Fauvre; Margot Machu; Audrey Merienne; Nadia Vie; Thomas Bessede; Mathilde Robin; Veronique Garambois; Clara Taffoni; Nadine Laguette; Nadine Gervois-Segain; Anne Jarry; Nathalie Labarriere; Yves Allory; Christel Larbouret; Laurent Gros; Diego Tosi; David B. Solit; Philippe Pourquier; Nadine Houédé; Celine Gongora

doi:10.1002/ctm2.70011

Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (9) : e70011 DOI: 10.1002/ctm2.70011

LETTER TO THE JOURNAL

STING-ATF3/type I interferon crosstalk: A potential target to improve anti-tumour immunity in chemotherapy-treated urothelial carcinoma

Author information +

History +

PDF

Cite this article

Download citation ▾

Alexandra Fauvre, Margot Machu, Audrey Merienne, Nadia Vie, Thomas Bessede, Mathilde Robin, Veronique Garambois, Clara Taffoni, Nadine Laguette, Nadine Gervois-Segain, Anne Jarry, Nathalie Labarriere, Yves Allory, Christel Larbouret, Laurent Gros, Diego Tosi, David B. Solit, Philippe Pourquier, Nadine Houédé, Celine Gongora. STING-ATF3/type I interferon crosstalk: A potential target to improve anti-tumour immunity in chemotherapy-treated urothelial carcinoma. Clinical and Translational Medicine, 2024, 14(9): e70011 DOI:10.1002/ctm2.70011

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Hassler MR, Bray F, Catto JWF, et al. Molecular characterization of upper tract urothelial carcinoma in the era of next-generation sequencing: a systematic review of the current literature. Eur Urol. 2020; 78: 209-220.

[2]	Munoz JJ, Ellison LM. Upper tract urothelial neoplasms: incidence and survival during the last 2 decades. J Urol. 2000; 164: 1523-1525.

[3]	Tosi D, Pérez-Gracia E, Atis S, et al. Rational development of synergistic combinations of chemotherapy and molecular targeted agents for colorectal cancer treatment. BMC Cancer. 2018; 18: 812.

[4]	Li T, Chen ZJ. The cGAS-cGAMP-STING pathway connects DNA damage to inflammation, senescence, and cancer. J Exp Med. 2018; 215: 1287-1299.

[5]	Aricò E, Castiello L, Capone I, Gabriele L, Belardelli F. Type I interferons and cancer: an evolving story demanding novel clinical applications. Cancers. 2019; 11: 1943.

[6]	Labzin LI, Schmidt SV, Masters SL, et al. ATF3 is a key regulator of macrophage IFN responses. J Immunol Baltim Md 1950. 2015; 195: 4446-4455.

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.